HK1099313A1 - Processes for preparing eptifibatide and pertinent intermediate compounds - Google Patents

Processes for preparing eptifibatide and pertinent intermediate compounds

Info

Publication number
HK1099313A1
HK1099313A1 HK07105387.3A HK07105387A HK1099313A1 HK 1099313 A1 HK1099313 A1 HK 1099313A1 HK 07105387 A HK07105387 A HK 07105387A HK 1099313 A1 HK1099313 A1 HK 1099313A1
Authority
HK
Hong Kong
Prior art keywords
eptifibatide
processes
fragment
intermediate compounds
preparing
Prior art date
Application number
HK07105387.3A
Other languages
English (en)
Inventor
Guojie Ho
Antoinette D Paone
Luciano Forni
Catherine Detollenaere
Brice Bonnett
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of HK1099313A1 publication Critical patent/HK1099313A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Combined Means For Separation Of Solids (AREA)
HK07105387.3A 2004-04-08 2007-05-22 Processes for preparing eptifibatide and pertinent intermediate compounds HK1099313A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56045304P 2004-04-08 2004-04-08
PCT/US2005/011873 WO2005100381A2 (en) 2004-04-08 2005-04-08 Processes for preparing eptifibatide and pertinent intermediate compounds

Publications (1)

Publication Number Publication Date
HK1099313A1 true HK1099313A1 (en) 2007-08-10

Family

ID=34956145

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07105387.3A HK1099313A1 (en) 2004-04-08 2007-05-22 Processes for preparing eptifibatide and pertinent intermediate compounds
HK10112216.1A HK1145691A1 (en) 2004-04-08 2010-12-30 Processes for preparing eptifibatide and pertinent intermediate compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK10112216.1A HK1145691A1 (en) 2004-04-08 2010-12-30 Processes for preparing eptifibatide and pertinent intermediate compounds

Country Status (21)

Country Link
US (2) US7674768B2 (ko)
EP (2) EP2204383B1 (ko)
JP (2) JP4926942B2 (ko)
KR (1) KR101238133B1 (ko)
CN (1) CN1972960B (ko)
AT (2) ATE433997T1 (ko)
AU (1) AU2005233603B2 (ko)
CA (1) CA2562157C (ko)
CY (2) CY1109357T1 (ko)
DE (1) DE602005014956D1 (ko)
DK (2) DK2204383T3 (ko)
ES (2) ES2328713T3 (ko)
HK (2) HK1099313A1 (ko)
HR (2) HRP20090490T1 (ko)
ME (2) ME01063B (ko)
MX (1) MXPA06011904A (ko)
PL (2) PL1735345T3 (ko)
PT (2) PT1735345E (ko)
RS (2) RS51182B (ko)
SI (2) SI2204383T1 (ko)
WO (1) WO2005100381A2 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582083A1 (en) * 2004-10-04 2006-04-20 Novetide, Ltd. A counterion exchange process for peptides
NL2000126C2 (nl) * 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.
MX2010008655A (es) * 2008-02-06 2010-10-06 Biocon Ltd Un metodo para purificar un peptido.
WO2009150657A1 (en) * 2008-06-09 2009-12-17 Natco Pharma Limited Improved process for preparation of eptifibatide by fmoc solid phase synthesis
CN101538314B (zh) * 2009-01-13 2012-10-03 深圳翰宇药业股份有限公司 一种纯化爱啡肽的方法
CN101747412A (zh) * 2009-12-30 2010-06-23 江苏诺泰制药技术有限公司 一种依替非巴肽的合成制备工艺
CN102174081B (zh) * 2011-03-09 2013-05-29 杭州华津允上医药有限公司 埃替非巴肽及其前体的制备方法
CN102827249A (zh) * 2011-06-14 2012-12-19 江苏豪森医药集团连云港宏创医药有限公司 一种依替巴肽的液相合成方法
CN103408637B (zh) 2013-06-27 2015-12-02 深圳翰宇药业股份有限公司 一种爱啡肽的制备方法
CN104710509B (zh) * 2013-12-11 2018-01-02 深圳翰宇药业股份有限公司 一种爱啡肽的制备方法
CN108250265A (zh) * 2016-12-29 2018-07-06 北京中科亚光生物科技有限公司 一种合成含有分子内二硫键的多肽的新工艺
CN110894212B (zh) * 2018-08-24 2021-06-04 翰宇药业（武汉）有限公司 一种合成依替巴肽硫醚的方法
CN109251234A (zh) * 2018-10-08 2019-01-22 重庆科脉生物化工有限公司 一种抗血小板聚集药物爱啡肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2616785B1 (fr) * 1987-06-19 1989-10-06 Solvay Composes guanidiniques comprenant un ion tetraphenylborate substitue et procede d'obtention de ces composes et utilisation des composes lors de la synthese peptidique
US5686568A (en) * 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregration inhibitors
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
BE1007184A3 (fr) * 1993-06-18 1995-04-18 Solvay Procede de preparation d'un amide d'alpha-aminoacide, utilisable en synthese peptidique.
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
CA2484594C (en) * 2002-05-03 2012-06-26 Avecia Limited Process for the synthesis of peptides
ES2237356T3 (es) * 2003-04-07 2007-04-01 Novetide Ltd. Procedimiento para la produccion de peptidos ciclicos.
NL2000126C2 (nl) 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.

Also Published As

Publication number Publication date
US20100105609A1 (en) 2010-04-29
EP2204383A1 (en) 2010-07-07
ME01063B (me) 2012-10-20
PT2204383E (pt) 2011-10-31
HK1145691A1 (en) 2011-04-29
EP1735345A2 (en) 2006-12-27
ME01260B (me) 2013-06-20
DE602005014956D1 (de) 2009-07-30
SI2204383T1 (sl) 2011-11-30
JP2012111756A (ja) 2012-06-14
EP1735345B1 (en) 2009-06-17
DK2204383T3 (da) 2011-10-17
JP2007537161A (ja) 2007-12-20
EP2204383B1 (en) 2011-08-10
CN1972960A (zh) 2007-05-30
MXPA06011904A (es) 2007-01-25
HRP20110812T1 (en) 2011-11-30
AU2005233603A1 (en) 2005-10-27
RS51929B (en) 2012-02-29
ES2328713T3 (es) 2009-11-17
PT1735345E (pt) 2009-09-11
SI1735345T1 (sl) 2010-01-29
KR20070015537A (ko) 2007-02-05
AU2005233603B2 (en) 2011-07-21
ATE433997T1 (de) 2009-07-15
PL1735345T3 (pl) 2009-12-31
US20060036071A1 (en) 2006-02-16
RS51182B (sr) 2010-10-31
WO2005100381A2 (en) 2005-10-27
DK1735345T3 (da) 2009-10-26
JP4926942B2 (ja) 2012-05-09
HRP20090490T1 (en) 2009-10-31
US7674768B2 (en) 2010-03-09
CY1111904T1 (el) 2015-11-04
ATE519781T1 (de) 2011-08-15
CA2562157C (en) 2013-09-10
PL2204383T3 (pl) 2012-01-31
CY1109357T1 (el) 2014-07-02
ES2369872T3 (es) 2011-12-07
KR101238133B1 (ko) 2013-03-04
WO2005100381A3 (en) 2006-07-27
CA2562157A1 (en) 2005-10-27
CN1972960B (zh) 2010-05-12

Similar Documents

Publication Publication Date Title
HRP20110812T1 (en) Processes for preparing eptifibatide and pertinent intermediate compounds
UA93424C2 (en) Preparation of azoxystrobin
IL190333A (en) Process and intermediates for the synthesis of caspofungin
WO2009095933A3 (en) Improved and novel process for the preparation of bosentan
WO2010036329A3 (en) Process for making quinolone compounds
WO2010070667A3 (en) Process and intermediates for the preparation of 7-( (3-chloro-6-methyl-5,5-dioxo-6,ll-dihydrodibenzo (c, f) (1,2) thiazepin-11-yd amino) heptanoate
TN2010000219A1 (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
TW200740729A (en) Methods for preparing glutamic acid derivatives
IL206570A0 (en) Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use
ATE332307T1 (de) Wachstumhormonsekretionsförderer
MY148560A (en) Process for preparing phosphonates having alcoholic hydroxyl group
WO2012070896A3 (en) Synthetic method of enantiomerically pure 2,2'-dihydroxy-1,1'-binaphthyl-3-carboxylic acid
MX2009008093A (es) Procedimientos para la preparacion de compuestos de urea sustituidos con piperidinilo.
WO2004065302A3 (en) Crystalline modification of a manganese complex
WO2009027803A3 (en) Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid
SI1572615T1 (sl) Postopek za sintezo peptidov ki vsebujejo hidroksi prolinsko substrukturo
TW200637495A (en) Novel composite for inhibiting algae growth and use thereof

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: DELETION OF INVENTOR: BONNETT, BRICE

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190405